JAMA Clinical Reviews Obesity Medications
27 snips
Jul 22, 2024 Dr. Robert F. Kushner from Northwestern University discusses new weight-loss drugs for obesity management. Topics include nutrient-stimulated hormone-based meds, less common medications, comparing terzepatide to semaglutide, and future weight loss drug advancements. The focus is on improving overall health outcomes with successful interventions.
AI Snips
Chapters
Transcript
Episode notes
Weight Regain After Stopping Drugs
- Stopping these medications abruptly leads to regaining half to two-thirds of lost weight within a year.
- Research explores intermittent dosing, dose reduction, or switching to oral drugs to maintain weight loss.
Long-Term Use of Obesity Drugs
- Consider long-term medication for obesity, treating it like a chronic disease such as diabetes or hypertension.
- Continue drugs if well tolerated and effective; tapering or switching to cost-effective alternatives is under investigation.
Semaglutide Long-Term Safety
- Semaglutide has been widely used for years at lower doses for diabetes with no new safety concerns.
- Ongoing surveillance shows it remains safe for long-term use in obesity treatment.